Related Experiment Video

Updated: Jun 16, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

17q12-21 - the pursuit of targeted therapy in breast cancer

R W Glynn1, N Miller, M J Kerin

  • 1Department of Surgery, Clinical Science Institute, National University of Ireland, Costello Road, Galway, Ireland. ronanglynn@doctors.org.uk

Cancer Treatment Reviews
|January 27, 2010
PubMed
Abstract

Insights

Investigating genes near HER2/neu, like TOP2A, GRB7, STARD3, and RARA, offers new therapeutic targets for breast cancer. These genes are crucial for developing personalized treatment strategies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • HER2/neu amplification is a key factor in breast cancer management.
  • Research is exploring genes on chromosome 17 near HER2/neu for new therapeutic insights.

Purpose of the Study:

  • To review the role of genes in the HER2/neu amplicon in breast cancer pathogenesis.
  • To explore how these genes can inform the development of novel targeted therapies.

Main Methods:

  • This review focuses on four genes within the HER2/neu amplicon: TOP2A, GRB7, STARD3, and RARA.
  • Evidence regarding the clinical relevance and biological function of these genes is discussed.

Main Results:

  • TOP2A overexpression correlates with HER2/neu amplification and response to anthracycline chemotherapy.
  • GRB7 is implicated in breast, gastric, and esophageal cancers and is part of Oncotype DX.
  • STARD3 is relevant to hormone-receptor-positive breast cancer, and RARA may address resistance to all-trans retinoic acid (ATRA).

Conclusions:

  • The investigated genes (TOP2A, GRB7, STARD3, RARA) show potential as therapeutic targets.
  • Further research into these genes is essential for advancing personalized breast cancer treatment strategies.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...